IL23R and metabolic dysfunction-associated steatohepatitis: In summary, we present the evidence that Il23r-/- mice are not protected from liver inflammation and fibrosis in two NASH preclinical models, thus suggesting that targeting IL-23 signaling alone may not be an effective therapeutic approach for NASH.